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Porphobilinogen synthase (PBGS) synthesizes porphobilinogen 2 (PBG), the common precursor of
all natural tetrapyrroles, through an asymmetric condensation of two molecules of 5-aminolevulinic acid
1 (ALA). Symmetrically linked dimers 7–11 derived from levulinic acid 3 (g-oxovaleric acid) have been
synthesized to mimic the assumed bisubstrate bound to the active site of the enzyme. Their inhibition
potential was characterized by determination of the IC50 and Ki values using PBGS from Pseudomonas
aeruginosa. The polarity and the size of the functional group linking the two levulinic acid 3 units have a
strong influence on the inhibition behavior.
Introduction. – Porphobilinogen synthase (PBGS), also called 5-aminolevulinate
dehydratase (ALAD; E. C. 4.2.1.24), catalyzes the condensation of two molecules of 5-
aminolevulinic acid (ALA, 1) to produce porphobilinogen (PBG, 2) [1] [2] which is a
committed intermediate in the biosynthesis of tetrapyrrolic natural products like
porphyrins and chlorophylls.
PBGS has been isolated and studied since 1953 [3]. The order of binding the two
substrates to the enzyme has been determined by Jordan and Seehra [4]: binding of
ALA (1) to the P site of the enzyme, first, and binding of the future acetic acid side
ALA (1) second. The synthesis of PBG (2) requires the sequential formation of both a
CC bond and a CN bond between the substrate molecules. The CC bond is
formed by an aldol condensation; the CN bond by a Schiff base formation.
Consequently two sequences for the catalytic mechanism are possible (Scheme 1).
Both possibilities have been discussed [5–8] but a formal proof in favor of one of the
mechanisms is still missing.
The active form of PBGS is a homo-octamer, as documented by crystal structures
from yeast [9], Escherichia coli [6], Pseudomonas aeruginosa [10], Homo sapiens [11],
and Chlorobium vibrioforme [12]. The monomers have all a TIM-barrel structure
[9] [13]. The active site, which is covered by a loop (@active-site flapA), is situated at the
C-terminal end of the bx-strand above the central barrel cavity. The influence of
bivalent metal ions (Zn2þ and/or Mg2þ ) on the catalytic activity of PBGS has been
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intensively studied [14–16]. The observed metal dependance has been used as basis to
tentatively categorize PBGS from different sources.
For several years, our group has been investigating the mechanism of PBGS isolated
from Rhodobacter spheroides [17] and from Escherichia coli [5] by systematic
inhibition studies. To test the recognition sites, a series of substrate analogs, product
analogs and analogs of postulated intermediates were synthesized, and their inhibition
potentials were determined. The results show that two carboxylate groups and two g-
keto groups are essential for a good recognition of the inhibitors in the active site
[18] [19].
It has been known for many years that the substrate is covalently bound to the P-site
lysine [4]. Accordingly, the inhibitor levulinic acid (¼4-oxopentanoic acid; 3) and the
substrate 5-aminolevulinic acid (1) have been observed crystallographically to form a
Schiff base to this lysine residue [6] [20] [21]. The P-site has, therefore, been well
characterized. The two irreversible inhibitors, 4-oxosebacic acid (¼4-oxodecanedioic
acid; 4) and 4,7-dioxosebacic acid 5, have been produced to mimic one of the two
possible reaction intermediates in which the CN bond-formation has been observed
first [8] [22]. The crystal structures of these ligands with Zn-dependent enzymes show
that both inhibitors 4 and 5 form a Schiff base with P-side lysine [7]. These interactions
are similar to all other ligands bound to the P-site exclusively, which have been studied
so far. In the case of the 4,7-dioxosebacic acid (5), two covalent linkages between the
enzyme and the inhibitor have been observed. The crystal structure reveals the
presence of a second Schiff base in the A-site. Observation of this Schiff base indicates
the possibility that A-side ALA might form, during the reaction, a bond to the A-site
lysine.
Recently, the structure determination of the complex between PBGS and 5-
fluorolevulinic acid (6) showed that two identical substrate analogs may bind at the
Scheme 1
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same time to the active site [23]. This X-ray structure provides a detailed model of the
native substrate–enzyme complex and fully identifies all residues involved in A-site as
well as P-site formation for Zn-independent PBGS. It reveals that an alkaline metal ion
may be required in Mg-dependant PBGS to stabilize ALA (1) in a defined
conformation in the polar A-site and modulate the activity of P-side ALA (1) [23].
The crystal structures are compatible with the proposed presence of two Schiff
bases between the two ALA (1) substrates and the lysine residues in the active site, and
allows to identify the residues responsible for the recognition of the carboxylic moiety
in the A-site. Because of the formation of the two Schiff bases with the substrate, the
irreversible inhibitor 4,7-dioxosebacic acid (5) could also be interpreted as a
bisubstrate analog as well as an analog of the postulated intermediate. The aim of
this investigation was to contribute to our knowledge about the active site of the
enzyme and to elucidate possible mechanisms for the transformation. We have decided
to synthesize a new generation of bisubstrate analogs 7–11 in order to understand the
bonding of the 4,7-dioxosebacic acid (5) to the enzyme. The design features of these
inhibitors are: they should contain the two important groups (two carboxylate groups
and two g-keto groups) for a good recognition in the active site, and they should allow
to vary the length and the chemical nature of the linker. We report the synthesis of a
series of inhibitors where the acid–base character, and the size and polarity of the
linking group have been varied. To see if this new family of compounds were good
inhibitors, we have studied their inhibition potentials for the Mg-dependant PBGS
from Pseudomonas aeruginosa by determination of their half maximal inhibition
concentrations, the IC50 value, their modes of inhibition, and their constants of
inhibition, the Ki value.
Results and Discussion. – Synthesis. The five specifically designed compounds 7–11
are bisubstrate analogs and contain the two important groups (COOH and g-oxo
functions) for a good recognition in the active site. The difference between the five
potential PBGS inhibitors 7–11 is the linker which can be an O-, N-, or S-atom, or
bulkier moities as a sulfinyl or sulfonyl groups. These bisubstrate analogs were
synthesized to test the influence of 1) the prolonged linker size compared to 4,7-
dioxosebasic acid (5) and 2) the volume and polarity of their linker moiety on their
potency to inhibit PBGS. The synthesis of the bisubstrate analogs 7–11 is highlighted in
the Schemes 2–4.
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The bromo compound 12 was the precursor for the five targeted inhibitors 7–11
and has already been described in the literature [24]. First, we tried to synthesize the O-
linked diacid 7 using classicalWilliamson conditions (Scheme 2). The hydroxy ester 13
was synthesized from 12 according to the procedure described in [25], but the
Williamson reaction between the compounds 12 and 13 gave only traces of the desired
O-linked diester 14. We have decided to change the OH function of 13 to a better
leaving group, e.g., a tosyl (Ts) group. For this purpose, we have used the conditions of
Still and Daoquan applied to a a-cetol [26]. The authors obtained a mixture of the
protected alcohol and the corresponding ether. The procedure consisted of treating the
alcohol 13 with p-toluenesulfonyl chloride (TsCl) and Et3N in CH2Cl2. The best
conditions, i.e., 1.2 equiv. of TsCl at room temperature for 20 h, gave 14, without
traces of the protected alcohol, in 82% yield (Scheme 2). The yield decreased
considerably, compared to the optimal value, if the number of equivalents of TsCl was
modified. When the reaction was run at lower temperatures, a mixture of 14 and the
protected alcohol was obtained. The acidic hydrolysis of 14 gave the desired compound 7.
The best way to synthesize the NH-linked diacid 8 was to protect the amino group
during the alkylation step followed by the deprotection of the N-atom (Scheme 3). The
alkylation of p-toluenesulfonamide with 12 in the presence of a base formed the desired
N-linked diester 15. The attempts using the same transformation with the (tert-
butoxy)carbonyl (Boc) and the (benzyloxy)carbonyl protecting groups at the N-atom
function were not successful. Classical hydrolysis conditions were tried on 15, but only
the hydrolysis of the two ester functions could be observed. The oxo groups in 15 did
not survive the reductive conditions applied for the deprotection of the secondary
amine moiety. For this reason, the two oxo groups had to be protected, and, in our
hands, the best way was to use acetal groups. The protection of the oxo groups with 1,2-
bis(trimethylsilyloxy)ethane afforded 16. The deprotection of the amine with the
sodium naphthalenide [27] [28] gave 17. The final step to obtain the desired compound
Scheme 2
a) Br2, MeOH, 108 to reflux, 3.5 h; 50%. b) Formic acid, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), r.t.,
1 h, Al2O3; 47%. c) p-Toluenesulfonyl chloride (TsCl), Et3N, CH2Cl2, r.t., 20 h; 82%. d) 6nHCl, 508, 2 h;
94%.
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8 was the deprotection of the oxo groups. As acid-catalyzed hydrolysis is the most
common method for the deprotection of acetals, 17 was treated with conc. HCl
overnight at 808, and the formation of 8 was observed. During this reaction, a
transesterification between the resulting ethane-1,2-diol and 8 was observed. To avoid
this problem, we tried an azeotropic distillation with diphenyl ether or heptane in order
to remove the water from the reaction medium. However, we did not succeed to isolate
8. Finally, a change of pH to 2–3 at the end of the reaction with an aqueous solution of
NaOH, followed by the evaporation of the solvent and a reprecipitation in a mixture of
MeOH/Et2O, resulted in the isolation of 8. The isolated product contained small
concentrations of NaCl, which did not interfere with the kinetic measurements.
The S-linked diacid 9 was easily obtained by condensation from the corresponding
halogen compounds (Scheme 4). The S-linked diester 18was synthesized from 12 in the
Scheme 3
a) p-Toluenesulfonamide, K2CO3, acetone, reflux, 15 h, Ar; 62%. b) 1,2-Bis(trimethylsiloxy)ethane,
trimethylsilyl trifluoromethanesulfonate (TMSOTf), CH2Cl2, 788 to r.t., 5 h, Ar; 82%. c) Na,
Naphthalene, 1,2-dimethoxyethane (DME), 788, Ar; 78%. d) Conc. HCl, 808, overnight; 6%.
Scheme 4
a) Na2S, acetone/H2O, r.t., 5.5 h; 79%. b) HCl 6n, 508, 2 h; 89%. c) Monoperoxyphthalic acid magnesium
salt hexahydrate (MMPP), EtOH 95%, r.t., 20 min, 84%. d) meta-Chloroperbenzoic acid (m-CPBA),
CH2Cl2, 408 to r.t., 170 min, 85%. e) 6n HCl, r.t., 160 min, 75%.
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presence of Na2S. The acidic hydrolysis of 18 gave the desired compound 9. Sulfur
compounds were easily oxidized to sulfoxide or sulfone compounds depending on the
reaction conditions. The oxidation of 18 with 3.5 or 1.2 equiv. of m-chloroperbenzoic
acid (mCPBA) gave the SO2-linked diester 19 and the corresponding SO-linked
diester, respectively. The acidic hydrolysis of 19 led to the desired SO2-linked diacid 11
(Scheme 4). Classical hydrolysis and enzymatic hydrolysis (with pig liver esterase)
conditions were tested on the SO-linked diester, but the desired compound 10 was not
obtained. At this stage, the oxidation with mCPBA of 9 was tried without success. The
use of the magnesium monoperoxyphthalate hexahydrate (MMPP) resulted in the
oxidation of 9 into a mixture of the desired SO-linked diacid 10 and the SO2-linked
diacid 11 (Scheme 4). The use of 1.5 equiv. of MMPP at 408 gave a mixture 10/11 with a
ratio of 37 :63. The product distribution could be improved to 96 :4 when 0.8 equiv. of
MMPP at room temperature for 20 min were used. This purity was sufficient for our
kinetic studies.
Inhibition Studies. As an initial test, the IC50 values of the bisubstrate analogs 7–11
were determined (Table) according to the method described in [29]. When measuring
the IC50 values, the time-dependence of inhibition was detected. Specific tests showed
time-dependent inhibition for all compounds except 7. The mode of inhibition for 8–11
was determined to be slow-reversible, and the apparent Ki values of these inhibitors
were measured as described in the Exper. Part (Table and Fig. 1). For 7, the mode of
inhibition was determined to be mixed, fast reversible, and Ki and aKi values were
obtained by classicalMichaelis–Menten kinetics (Table and Fig. 2). Both methods gave
the same picture.
The best inhibitors for PBGS from Pseudomonas aeruginosa are compounds 7, 8,
and 9 (Table). SO-Linked diacid 10 and SO2-linked diacid 11 are weaker inhibitors. The
considerably smaller affinity of the compounds 10 and 11 towards the enzyme can be
explained by the increased bulkiness of the linker connecting the two identical g-oxo
pentanoic acid parts of the inhibitors. The bulkiness of the inhibitors 10 and 11
correlates with their decreased inhibition potential.
Discussion. – A series of five symmetric di-g-oxo diacid compounds 7–11 have been
synthesized in order to be tested with the enzyme PBGS from Pseudomonas
aeruginosa. The influence of 1) their increased linker size compared to 4,7-dioxosebacic
Table. Kinetic Values of Bisubstrate Analog Inhibitors
Compound IC50 [mm]a) Time dependence Ki [mm] aKi [mm]
7 0.960.03  982b) 4200340
8 0.310.01 þ 20030c)
9 0.340.01 þ 6020c)
10 383 þ 108004600c)
11 9.90.4 þ 110003000d)
a) Determined with Eqn. 1. b) Determined using Michaelis–Menten kinetics. c) Determined with
Eqn. 3b. d) Determined with Eqn. 4.
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acid (5), and 2) the volume and polarity of their linker moiety on their potency to
inhibit PBGS from Pseudomonas aeruginosa have been determined.
Analysis of the IC50 values of these compounds showed that they are all potent
inhibitors for the PBGS from Pseudomonas aeruginosa. Three compounds, 7, 8 and 9,
seem to be very good inhibitors, as their IC50 values are better than for the 4,7-
Fig. 1. a) Plots of the absorbance measured at 555 nm, which is proportional to the formation of PBG, vs.
preincubation time of the inhibitor 9. . ¼ 0.1 mm, *¼0.2 mm, !¼0.4 mm, ~¼0.6 mm, &¼0.8 mm. The
curves were calculated based on Eqn. 2. b) The plot of the inhibitor concentration vs. kobs dertermined
from Fig. 1,a. The straight line is a least-square fit based on Eqn. 3b. The Ki app corresponds to the y-axis
intercept.
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Fig. 2. a) Plots of absorbance at 555 nm, which is proportional to the formation of PBG, vs. substrate
concentration for different concentrations of the inhibitor 7. *¼0 mm, *¼0.33 mm, !¼0.66 mm, ~¼
1.0 mm, &¼1.5 mm, &¼2.0 mm. The curves are least-square fits to the Michaelis–Menten equation
A ¼ Amax app  ½S
KM app þ ½S
. b) The straight line is a least square fit to the equation ½I ¼ Amax
KM
 KM app
Amax app
Ki Ki,
which can be deduced for mixed inhibi tors. The Ki value corresponds to the
y-axis intercept. c) The straight line is a least-square fit to the equation ½I ¼ Amax
Amax app
 aKi  aKi . The
aKi value corresponds to the y-axis intercept. The following symbols and abreviations were used: [I]:
inhibitor concentration, KM : Michaelis coefficient, KMapp : apparent Michaelis coefficient in presence of
inhibitor (KM app¼KM in absence of inhibitor), Amax: maximal absorption (linear to maximal velocity for
a given enzyme concentration),Amaxapp : apparent maximal absorption in presence of inhibitor (Amaxapp¼
Amax in absence of inhibitor), Ki : inhibition coefficient for interaction between free enzyme and
inhibitor, aKi : inhibition coefficient for interaction between enzyme–substrate complex and inhibitor.
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dioxosebasic acid (5 ; IC50¼2.1 mm) [8]. The IC50 values of these three inhibitors are
also by roughly a factor of ten smaller than the IC50 value of hydroxy-levulinic acid
(IC50¼4.05 mm; data not shown), which is known to be a good substrate analogue.
Within the set of inhibitors, NH-linked diacid 8, which is an H-bond donor in its
protonated form, and S-linked diacid 9 which is a weak H-bond acceptor, are the most
potent inhibitors with respect to their IC50 values. Both have relatively small linker
moieties. The other inhibitor with a small linker moiety, O-linked diacid 7, is an H-bond
acceptor and exhibits an IC50 value which is by one order of magnitude higher than the
values for compounds 8 and 9. Interestingly, 7 differs from the other inhibitors in
showing fast reversible binding. Nevertheless the Ki values of the 7–9 indicate a
comparable inhibition potency.
The weakest inhibitors in the set, indicated by either IC50 or Ki values, are SO-
linked diacid 10 and SO2-linked diacid 11 which carry bulky H-bond-accepting linker
groups. These results can be tentatively interpreted as an indication that an optimal size
for dioxo-diacid inhibitors is reached with compounds 7, 8, and 9. Also H-bond-
accepting moieties (i.e., 10 and 11) in this position seem to be obstructive. Based on
these promising findings, we have planed further kinetic studies and co-crystallization
experiments of the new compounds 7–11 with PBGS from Pseudomonas aeruginosa.
These results have already been published since the submission of the manuscript [29].
This research was suported by a grant from the Swiss National Science Foundation (Grant 2000-
104007) to R. N., as well as grants from the Deutsche Forschungsgemeinschaft and the Fonds der
Chemischen Industrie to N. F.-D.
Experimental Part
General. THF (Fluka, purum) was distilled under N2 over K and benzophenone; 1,2-dimethoxy-
ethane (DME) was distilled under N2 over Na and benzophenone; other solvents (Fluka, puriss.) were
used without further treatment. TLC: silica gel 60 F254 plates (aluminium, 0.2 mm;Merck). Flash column
Fig. 2 (cont.)
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chromatography (FC): silica gel 60 (0.04–0.063 mm, Fluka). M.p.: B7chi 510 apparatus, uncorrected. IR
Spectra: Perkin-Elmer 1720X FT-IR spectrophotometer; in cm1. NMR Spectra: Bruker AMX-400 and
Varian Gemini XL-200; Me4Si as external reference (d¼0); temp.: 298 K; all coupling constants J in Hz.
MS: EI (70 eV): PolarisQ (Agilent); ESI and APCI: ThermoFinnigan LCQ (San Jose´, California); HR-
MS: Bruker BioAPEX II Daltonics. Elemental analyses were performed by @lAEcole dAinge´nieurA of
Fribourg.
Methyl 5-Bromo-4-oxopentanoate (12) [24]. Br2 (44 ml, 860 mmol) was added dropwise to levulinic
acid (3 ; 100 g, 860 mmol) in MeOH (800 ml) at 08 for 2 h. After the addition was completed, the mixture
was stirred at reflux for 90 min. After removal of the solvent, the residue was dissolved in CH2Cl2
(800 ml) and washed with NaHCO3 (1200 ml) and with H2O (3200 ml). The org. layer was dried
(MgSO4) and concentrated, and the residue was purified by distillation (Widmer column, 50 cm, 7 ·102
mm Hg) to afford 12 (91.6 g, 50%). Colorless liquid. B.p. 608 at 7 ·102 mm Hg. Rf (hexane/AcOEt 1 :2)
0.5. IR (KBr, film): 2999m, 2954s, 2849w, 1733s, 1439s, 1411s, 1360s, 1322s, 1208s, 1176s, 1123m, 1079s,
1024s, 988s, 862m, 844m, 694m. 1H-NMR (400 MHz, CDCl3): 3.95 (s, CH2(5)); 3.67 (s, Me); 2.95 (t, J¼
6.5, CH2(3)); 2.65 (t, J¼6.5, CH2(2)). 13C-NMR (100 MHz, CDCl3): 201.1 (C(4)); 173.2 (C(1)); 52.4
(Me); 34.8 (C(3)); 34.5 (C(5)); 28.5 (C(2)).
Methyl 5-Hydroxy-4-oxopentanoate (13) [25]. 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU; 11.7 g,
77.0 mmol) was added dropwise to a mixture of 12 (12.6 g, 60.2 mmol) and of HCOOH (3.44 g,
74.7 mmol) in benzene (85 ml) at 108. The soln. was stirred at r.t. for 1 h, and then the reaction was
quenched with H2O (100 ml). The mixture was extracted with CH2Cl2 (3100 ml), and the combined
org. extracts were washed successively with 0.1nHCl (250 ml) andH2O (100 ml). The org. layer was dried
(Na2SO4) and concentrated, and the residue was hydrolyzed on a column of aluminium oxide (neutral;
CH2Cl2/MeOH 1 :1). The crude product was purified by micro-distillation (P 6.5 ·102 mmHg) to give 13
(4.10 g, 47%). Colorless liquid. B.p. 55–568 at 6.5 · 102 mm Hg. Rf (hexane/AcOEt 2 :1) 0.2. IR (KBr,
film): 3450s (br.), 3001m, 2956m, 2918m, 2852m, 1729s (br.), 1439s, 1413s, 1364s, 1320s, 1256s, 1211s,
1175s, 1125m, 1079s, 1016s, 980m. 1H-NMR (400 MHz, CDCl3): 4.30 (s, CH2(5)); 3.67 (s, Me); 2.68 (s,
CH2(2), CH2(3)). 13C-NMR (100 MHz, CDCl3): 208.5 (C(4)); 173.1 (C(1)); 68.5 (C(5)); 52.3 (Me); 33.1
(C(3)); 27.8 C(2)).
Methyl 5-[4-(Methoxycarbonyl)-2-oxobutoxy]-4-oxopentanoate (14). TsCl (3.14 g, 16.4 mmol) was
added to 13 (2.03 g, 13.9 mmol) and Et3N (1.66 g, 16.5 mmol) in CH2Cl2 (20 ml), and the mixture was
stirred at r.t. for 20 h. The mixture was concentrated, and the residue was purified by FC (1% AcOEt in
CH2Cl2) to afford 14 (1.57 g, 82%). Pale yellow liquid. Rf (1% AcOEt in CH2Cl2) 0.4. IR (KBr, film):
2997m, 2954s, 1733s, 1632m, 1438s, 1403s, 1359s, 1328s, 1200s (br.), 1088s, 1025s, 994s, 967m, 872m, 844m,
818m, 775s, 727m. 1H-NMR (400 MHz, CDCl3): 4.15 (s, CH2(5)); 3.68 (s, Me); 2.90 (t, J¼6.4, CH2(3));
2.67 (t, J¼6.4, CH2(2)). 13C-NMR (100 MHz, CDCl3): 201.4 (C(4)); 172.9 (C(1)); 52.1 (Me); 48.3 (C(5));
34.4 (C(3)); 27.9 (C(2)). EI-MS: 179, 167, 165 (100), 135, 133, 115, 97, 87, 69, 55.
5-(4-Carboxy-2-oxobutoxy)-4-oxopentanoic Acid (7). A soln. of 14 (0.64 g, 2.33 mmol) and HCl 6n
(75 ml) was stirred at 508 for 2 h. The solvent was evaporated, and the residue was purified by FC
(MeOH) and then by recrystallization in hexane/AcOEt to provide 7 (0.45 g, 78%). White solid. M.p.
868. Rf (CH2Cl2/AcOEt 10 :3) 0.35. IR (KBr): 3445–2316 (br.), 1736s, 1690s, 1433m, 1410s, 1366m,
1324m, 1296s, 1212m, 1096m, 1038m, 951m, 863w, 770m, 732w, 621m. 1H-NMR (400 MHz, CDCl3): 4.14
(s, CH2(5)); 2.90 (t, J¼6.4, CH2(3)); 2.71 (t, J¼6.4, CH2(2)). 13C-NMR (100 MHz, CDCl3): 201.3 (C(4));
178.3 (C(1)); 48.2 (C(5)); 34.2 (C(3)); 27.9 (C(2)). APCI-MS: 229 ([MH2OþH]þ ). EI-MS: 133, 101,
73, 55 (100).
Methyl 5-{[4-(Methoxycarbonyl)-2-oxobutyl](4-methylphenylsulfonyl)amino}-4-oxopentanoate
(15). p-Toluenesulfonamide (4.00 g, 23.4 mmol) and K2CO3 (6.60 g, 47.6 mmol) in acetone (150 ml)
were stirred at reflux for 50 min under Ar. Compound 12 (9.99 g, 47.8 mmol) was added dropwise with a
syringe, and the heterogenous mixture was stirred at reflux for 3 h. The solid was filtered, and the soln.
was concentrated. The residue was separated by FC (hexane/AcOEt (1 : 2)) and purified by
recrystallization in i-PrOH to afford 15 (6.24 g, 62%). White solid. M.p. 1098. Rf (hexane/AcOEt 1 :2)
0.32. IR (KBr): 3075w, 3063w, 3025w, 3012w, 2955m, 2940m, 2921m, 1739s, 1722s, 1599m, 1496w, 1451m,
1440s, 1414s, 1358s, 1329s, 1305s, 1200s, 1183s, 1174s, 1155s, 1119m, 1093s, 1019m, 998m, 983s, 975s, 887m,
881m, 816m, 804m, 781s, 716m, 662s, 555s, 540s. 1H-NMR (400 MHz, CDCl3): 7.68 (d, J¼8.4, HC(2,6)
10
of tosyl); 7.29 (d, J¼8.4, HC(3,5) of tosyl); 4.18 (s, CH2(5)); 3.65 (s, COOMe); 2.73–2.69 (m, CH2(3));
2.63–2.59 (m, CH2(2)); 2.42 (s, MeC(4) of tosyl). 13C-NMR (100 MHz, CDCl3): 204.2 (C(4)); 173.1
(C(1)); 144.0 (C(4) of tosyl); 136.0 (C(1) of tosyl); 129.8 (C(3,5) of tosyl); 127.6 (C(2,6) of tosyl); 56.6
(C(5)); 52.0 (COOMe); 34.1 (C(3)); 27.9 (C(2)); 21.7 (MeC(4) of tosyl). ESI-MS: 450 ([MþNa]þ ).
Anal. calc. for C19H25NO8S (427.48): C 53.39, H 5.89, N 3.28; found C 53.33, H 5.92, N 3.18.
Methyl 3-(2-{[({2-[2-(Methoxycarbonyl)ethyl][1,3]dioxolan-2-yl}methyl)(4-methylphenylsulfonyl)-
amino]methyl}[1,3]dioxolan-2-yl)propanoate (16). Trimethylsilyl trifluoromethanesulfonate (TMSOTf;
0.04 ml, 0.22 mmol) and 1,2-bis(trimethylsiloxy)ethane (1.29 g, 6.26 mmol) were added successively to 15
(1.02 g, 2.38 mmol) in CH2Cl2 (5 ml) at 408 and under Ar. The mixture was stirred at 408 for 1 h and
then at r.t. for 5 h. The org. layer was washed with NaHCO3 (275 ml), dried (Na2SO4), and
concentrated. The residue was purified by FC (hexane/AcOEt 1 :1) to afford 16 (1.0 g, 82%). Slimy
liquid. Rf (hexane/AcOEt 1 :1) 0.4. IR (KBr, film): 2953s, 2893s, 1732s, 1598s, 1495m, 1435s, 1335s, 1155s,
1091s, 1034s, 951s, 931s, 895s, 865m, 816s, 805s, 756s, 716m, 659s, 546s. 1H-NMR (400 MHz, CDCl3)2): 7.70
(d, J¼8.2, HC(2,6) of tosyl); 7.25 (d, J¼8.2, HC(3,5) of tosyl); 3.81–3.71 (m, HaC(4’,5’)); 3.69–
3.63 (m, HbC(4’,5’)); 3.66 (s, CH2(5)); 3.65 (s, COOMe); 2.40 (s, MeC(4) of tosyl); 2.32 (t, J¼7.5,
CH2(2)); 1.91 (t, J¼7.5, CH2(3)). 13C-NMR (100 MHz, CDCl3): 174.9 (C(1)); 142.9 (C(4) of tosyl); 138.9
(C(1) of tosyl); 129.8 (C(3,5) of tosyl); 127.8 (C(2,6) of tosyl); 110.5 (C(4)); 64.9 (C(4’,5’)); 51.7
(COOMe); 49.6 (C(5)); 31.1 (C(3)); 28.4 (C(2)); 21.6 (MeC(4) of tosyl). ESI-MS: 538 ([MþNa]þ ).
HR-MS: 538.1717 ([MþNa]þ ; calc. 538.1723).
3-{2-[({[2-(2-Carboxyethyl)[1,3]dioxolan-2-yl]methyl}amino)methyl][1,3]dioxolan-2-yl}propanoic
Acid (17). A soln. of sodium naphthalenide in freshly distilled 1,2-dimethoxyethane (DME) was
prepared by adding Na (0.21 g, 9.24 mmol) to a mixture of naphthalene (1.39 g, 10.9 mmol) in DME
(15 ml) and stirring the resulting mixture at r.t. for 2 h under Ar. A soln. of 16 (0.68 g, 1.33 mmol) in
DME (10 ml) was cooled at 788 under Ar. The sodium naphthalenide soln. was added dropwise to the
well-stirred soln. of 16, until a light green color persisted. The reaction was quenched with H2O (0.3 ml),
leading to complete decoloration. The soln. was concentrated, and the residue was purified by FC
(AcOEt/MeOH 2 :1 to 1 :2) to afford 17 (0.35 g, 78%). Pale yellow solid. M.p. 278. Rf (AcOEt/MeOH
1 :2) 0.19. IR (KBr): 3430s (br.), 2969m, 2899m, 1630s, 1567s, 1491m, 1407s, 1372m, 1303m, 1213m,
1138m, 1048m, 952w, 853w, 646w (br.). 1H-NMR (400 MHz, CD3OD)2): 4.08–4.04 (m, HaC(4’,5’));
4.03–4.00 (m, HbC(4’,5’)); 3.10 (s, CH2(5)); 2.27 (t, J¼7.3, CH2(2)); 1.98 (t, J¼7.3, CH2(3)). 13C-NMR
(100 MHz, CD3OD): 181.2 (C(1)); 109.7 (C(4)); 66.2 (C(4’,5’)); 52.4 (C(5)); 32.8 (C(2)); 32.6 (C(3)).
ESI-MS: 332 ([MH] ). HR-MS: 332.1346 ([MH] ; calc. 332.1345).
5-[(4-Carboxy-2-oxobutyl)amino]-4-oxopentanoic Acid 8. Compound 17 (1.14 g, 3.43 mmol) and
conc. HCl (10 ml) were stirred at 808 overnight. The pH was adjusted to 2–3 with an aq. soln. of NaOH,
and the soln. was concentrated. The residue was dissolved in MeOH, and the insoluble solid was filtred.
The solvent was removed, and the crude product was purified by recrystallization in MeOH/Et2O. The
beige solid 8 (0.06 g, 6%) was recovered by centrifugation. The yield was not optimized. M.p. 2078. IR
(KBr): 3459w, 2978m, 2950m, 2918m, 2759m, 2631m, 2544m, 1738s, 1487m, 1426m, 1399s, 1384s, 1324m,
1293m, 1221m, 1192m, 1133m, 1099s, 1066m, 1011s, 969s, 914s, 839m, 824m, 719m, 667m, 620m, 547m.
1H-NMR (200 MHz, D2O): 4.08 (s, CH2(5)); 2.74 (t, J¼6.5, CH2(3)); 2.46 (t, J¼6.5, CH2(2)). 13C-NMR
(100 MHz, D2O): 204.0 (m3), C(4)); 179.1 (C(1)); 53.9 (m3), C(5)); 35.5 (C(3)); 29.3 (C(2)). ESI-MS:
246 ([MþH]þ ), 268 ([MþNa]þ ), 244 ([MH] ). HR-MS: 246.0976 ([MþH]þ ; calc. 246.0978),
268.0796 ([MþNa]þ ; calc. 268.0797).
Methyl 5-{[4-(methoxycarbonyl)-2-oxobutyl]sulfanyl}-4-oxopentanoate 18. Na2S (3.79 g, 48.6 mmol)
in H2O (25 ml) was added to 12 (10.0 g, 47.9 mmol) in acetone (120 ml). The yellow soln. was stirred at r.t.
for 8 h before removal of the solvents. The residue was separated by FC (hexane/AcOEt 1 :2) and
purified by cold reprecipitation in MeOH/AcOEt to afford 18 (5.48 g, 79%). White solid. M.p. 328. Rf
(hexane/AcOEt 1 :2) 0.4. IR (KBr): 2950w, 2883w, 1735s, 1699s, 1436m, 1412s, 1382m, 1330s, 1292m,
1252m, 1205s, 1103m, 1020m, 991m, 864m, 627w. 1H-NMR (400 MHz, CDCl3): 3.67 (s, COOMe); 3.36
2) Assignments according to the C-atom numbering as for 15. Primed numbering is used for dioxolane
C-atoms.
3) The multiplet is explained by H/D exchange due to the NMR solvent.
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(s, CH2(5)); 2.88 (t, J ¼ 6.5, CH2(3)); 2.61 (t, J¼6.5, CH2(2)). 13C-NMR (100 MHz, CDCl3): 203.8 (C(4));
173.3 (C(1)); 52.2 (COOMe); 41.0 (C(5)); 35.9 (C(3)); 28.2 (C(2)). ESI-MS: 313 ([MþNa]þ ). Anal.
calc. for C12H18O6S (290.34): C 49.64, H 6.25; found C 49.80, H 6.27.
5-[(4-Carboxy-2-oxobutyl)sulfanyl]-4-oxopentanoic Acid (9). A soln. of 18 (1.54 g, 5.32 mmol) and
6n HCl (75 ml) was stirred at 508 for 2 h. The solvent was evaporated, and the residue was purified by
recrystallization in i-PrOH to give 9 (1.24 g, 89%). White solid. M.p. 1568. Rf (MeOH) 0.7. IR (KBr):
3384–2537 (br.), 1694s, 1445m, 1426m, 1408s, 1383s, 1364m, 1329s, 1285m, 1257m, 1228s, 1193m, 1143w,
1115w, 1096m, 1075m, 1040m, 907m, 888m, 865m, 618m, 525w, 505w. 1H-NMR (400 MHz, DMSO): 12.14
(s, COOH); 3.46 (s, CH2(5)); 2.76 (t, J¼6.5, CH2(3)); 2.41 (t, J¼6.5, CH2(2)). 13C-NMR (100 MHz,
DMSO): 204.5 (C(4)); 173.6 (C(1)); 40.6 (C(5)); 35.4 (C(3)); 27.7 (C(2)). ESI-MS: 285 ([MþNa]þ ), 280
([MþH2O]þ ), 263 ([MþH]þ ). Anal. calc. for C10H14O6S (262.28): C 45.79, H 5.38; found C 45.63, H
5.25.
5-[(4-Carboxy-2-oxobutyl)sulfonyl]-4-oxopentanoic Acid (11) . m-Chloroperbenzoic acid (m-
CPBA) (2.06 g, 11.9 mmol) was added dropwise to a soln. of 18 (1.00 g, 3.45 mmol) in CH2Cl2 (80 ml)
at 408. After 20 min, the cooling bath was removed, and the mixture was stirred at r.t. for 2.5 h.
NaHSO3 (25 ml) was added to the soln., and the org. phase was washed with Na2CO3 (150 ml) and
brine (250 ml), dried (MgSO4), and concentrated. The residue was separated by FC (hexane/AcOEt
1 :2) and purified by cold reprecipitation inMeOH/i-PrOH to provide 19 (0.94 g, 85%).White solid. M.p.
408. Rf (hexane/AcOEt 1 :2) 0.3. IR (KBr): 3001m, 2974m, 2957m, 2940m, 2921m, 1746s, 1717s, 1438m,
1416m, 1398m, 1383m, 1373m, 1364m, 1333m, 1314s, 1277m, 1257m, 1216s, 1196s, 1176s, 1142s, 1099m,
1081m, 1044w, 988m, 970m, 852m, 790m, 748m, 676w, 551m, 512m. 1H-NMR (400 MHz, CDCl3): 4.33 (s,
CH2(5)); 3.69 (s, COOMe); 2.95 (t, J¼6.3, CH2(3)); 2.65 (t, J¼6.3, CH2(2)). 13C-NMR (100 MHz,
CDCl3): 197.9 (C(4)); 172.6 (C(1)); 62.9 (C5)); 52.2 (COOMe); 39.2 (C(3)); 27.6 (C(2)). ESI-MS: 345
([MþNa]þ ). Anal. calc. for C12H18O8S (322.34): C 44.72, H 5.63; found C 44.84, H 5.62.
A soln. of 19 (4.4 g, 13.7 mmol) and 6n HCl (400 ml) was stirred at 508 for 160 min. The solvent was
evaporated, and the residue was purified by recrystallization in THF to give 11 (3.02 g, 75%). White
solid. M.p. 1568. IR (KBr): 3422–2565 (br.), 2967s, 2921s, 1723s, 1697s, 1429s, 1400s, 1372m, 1361m,
1327s, 1300m, 1256s, 1237s, 1206m, 1186m, 1153m, 1119s, 1079s, 1036m, 1018m, 942m, 866m, 855m, 648w,
522w, 486m. 1H-NMR (400 MHz, DMSO): 12.22 (s, COOH); 4.58 (s, CH2(5)); 2.84 (t, J¼6.5, CH2(3));
2.43 (t, J¼6.5, CH2(2)). 13C-NMR (100 MHz, DMSO): 198.7 (C(4)); 173.3 (C(1)); 63.3 (C(5)); 38.7
(C(3)); 27.4 (C(2)). ESI-MS: 293 ([MH] ). Anal. calc. for C10H14O8S (294.28): C 40.82, H 4.80; found
C 40.78, H 4.76.
5-[(4-Carboxy-2-oxobutyl)sulfinyl]-4-oxopentanoic Acid (10). Monoperoxyphthalic acid magnesi-
um salt hexahydrate (MMPP; 0.77 g, 1.55 mmol) in H2O (10 ml) was added to 9 (0.51 g, 1.95 mmol) in
EtOH (10 ml). The heterogeneous mixture was heated until solubilization and then stirred at r.t. for
20 min. The obtained solid was filtered and yielded 10. The soln. was concentrated, and the residue was
treated in MeOH. The insoluble solid was again filtered. The white solid 10 (0.45 g, 84%) was obtained
but was contamined with 4% of 11. M.p. 1728. Rf (AcOEt/MeOH 1 :1) 0.12. IR (KBr): 3275–2886 (br.),
1751m, 1700s, 1717s, 1446m, 1406m, 1357m, 1325m, 1301m, 1255w, 1230m, 1214m, 1166m, 1095m, 1031s,
1015m, 993m, 898w, 689w, 618w. 1H-NMR (400 MHz, DMSO): 12.18 (s, COOH); 4.13 (d, J¼14.7,
CHa(5)); 4.03 (d, J¼14.7, CHb(5)); 2.80 (dt, J¼18.3, J¼6.2, CHa(3)); 2.76 (dt, J¼18.3, J¼6.2, CHb(3));
2.44 (t, J¼6.2, CH2(2)). 13C-NMR (100 MHz, DMSO): 202.3 (C(4)); 173.5 (C(1)); 61.9 (C(5)); 38.7
(C(3)); 27.4 (C(2)). ESI-MS: 277 ([MH] ).
Biochemical Studies. PBGS Purification. The procedure for the PBGS isolation and purification has
been published in [29].
PBGS Assay and Determination of IC50 Values. The PBGS is a colorimetric assay based on the
reaction between PBG (2) and 4-(dimethylamino)benzaldehyde (EhrlichAs reagent) [30]. The assay
conditions were kinetic buffer (Bis-Tris propane, pH 8.5 (100 mm), MgCl2 (10 mm)), inhibitors (between
125 mm and 125 ·103 mm), PBGS (4 mg ml1), and ALA (1; 2 mm). PBGS and inhibitor were
preincubated for 30 min at 378 prior to addition of the ALA (1) soln., preheated to 378. Reaction was
allowed to proceed for 15 min and stopped by adding the mixture (350 ml) to the stop reagent (350 ml ;
25% Cl3CCOOH). After centrifugation (3 min, 13500 rpm), the supernatant (450 ml) was treated with
the EhrlichAs reagent (450 ml ; 4-(dimethylamino)benzaldehyde (0.4 g) in AcOH (10 ml) and HClO4
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(10 ml)). After 10–15 min, the quantity of product formed was determined by measuring the absorbance
at 555 nm (e¼60200 m1 cm1). The experimental data were fit against the Eqn. 1, assuming a linear
proportionality between the absorbance and the product concentration. The definitions of the
parameters are: v is the velocity, [I] is the inhibitor concentration (in mm), IC50 is the inhibitor
concentration giving 50% inhibition and h is the Hill coefficient.
vi=vo ¼ 1= 1þ I½ =IC50ð Þð Þh (1)
The values for IC50 to give the best fit to Eqn. 1 were determined by using the regression wizard of
sigmaplot 9.0.
Determination of Time-Dependent or -Independent Inhibition, Mode of Inhibition and Ki Values.
Time dependence of inhibition was determined by pre-incubating the inhibitor with a fixed concentration
of PBGS (4 mg ml1) and ALA (1; 2 mm) in kinetic buffer (Bis-Tris propane, pH 8.5 (100 mm), MgCl2
(10 mm)) between 30 s and 30 min. The PBGS activity was determined as described above. In case time-
independent inhibition was observed, the Ki values were established using Michaelis–Menten kinetics.
The apparent Michaelis constant, KMapp, and the maximal absorbance Amax (correlated linear to vmax)
were determined for each inhibitor concentration. For mixed inhibition behavior, plots of inhibitor
concentration vs. KMapp/Amaxapp and inhibitor concentration vs. 1/Amaxapp yield Ki and aKi , resp. For
inhibitors that show time-dependent behavior, mode of inhibition and potency were determined as
described by Copeland [31]. The dependance of product formation (measured at absorbance of 555 nm)
on the preincubation time of the inhibitor with the enzyme was determined. The obtained data were used
to determine kobs applying Eqn. 2:
A=A0 ¼ ekobs t (2)
The dependence of kobs on inhibitor concentration directly yields the apparent inhibition constant
Ki app through the application of Eqn. 3, with k4 representing the dissociation rate constant for a simple
reversible slow binding mode of time-dependent inhibition

Eþ I>k3
k4
EI

:
kobs ¼ k4  1þ ½I=Kið Þ (3a)
or
½I ¼ Ki  kobs=k4ð Þ Ki (3b)
So a plot of [I] vs. kobs yields Ki as y-axis intercept. In the case of 11, the apparent Ki value was only
determinable if a Hill coefficient h was introduced into Eqn. 3a to give Eqn. 4.
kobs ¼ k4  1þ ½I=Kið Þh
 
(4)
In this case Ki was determined via non-linear regression using sigmaplot 9.0.
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